

Mirum is here to help with study-related expenses

Reasonable study-related travel is covered for you and your loved one with Fragile X Syndrome who participate in the BLOOM clinical study.

These services include:



Ground transportation



Air travel



Accommodations

If you travel, related reasonable expenses including child care may be reimbursed as permitted by study site policies. Our study representatives will be able to provide more details.

Visit [mirumclinicaltrials.com/fragilexstudy](https://www.mirumclinicaltrials.com/fragilexstudy) to learn more about the BLOOM clinical study.



References: 1. Clinicaltrials.gov. NCT07209462. Updated October 24, 2025. Accessed October 30, 2025. <https://www.clinicaltrials.gov/study/NCT07209462> 2. Data on file. Mirum Pharmaceuticals, Inc. 3. Berry-Kravis EM, Harnett MD, Reines SA, et al. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. *Nat Med.* 2021;27(5):862-870. doi:10.1038/s41591-021-01321-w



For US Residents Only



A Mirum Clinical Study for Fragile X Syndrome
Information for Patients and Caregivers

Every inch can seem like a mile

Fragile X Syndrome can make everyday moments feel out of reach. **Together**, we can learn more through research.

Consider enrolling your male loved one in the BLOOM clinical study

If your male loved one has been diagnosed with Fragile X Syndrome, he may be eligible to enroll in the BLOOM clinical study. This clinical study is exploring if MRM-3379, an investigational medication, can safely and effectively help improve certain symptoms in male participants with Fragile X Syndrome.¹

Who can enroll?

Males aged 13–45 diagnosed with Fragile X Syndrome.

What's involved?

A brief screening period, followed by 12 weeks of treatment with 4 in-person visits with you and your loved one and 4 phone check-ins with just you, the caregiver.

Talk to your healthcare provider about participating.

Additional study requirements and exclusions apply. A study representative will discuss these with you during the screening period.

What is MRM-3379?

MRM-3379 is an investigational medication designed to work by increasing levels of a signaling molecule in the brain that is often lower in people with Fragile X Syndrome. When this molecule is low, it can affect how the brain communicates, which may impact learning, memory, and managing emotions. MRM-3379 aims to help increase this molecule in patients with Fragile X Syndrome.^{2,3}



For illustrative purposes only.

Study objectives

The BLOOM clinical study is currently enrolling males with Fragile X Syndrome ages 13 to 45 and aims to explore if this investigational medicine:

- Has any side effects and how well it is tolerated¹
- Is effective in managing certain symptoms of Fragile X Syndrome²

In this study, based on your loved one's age, he will receive either MRM-3379 or a placebo (a capsule with no active ingredient), taken orally twice a day.



For illustrative purposes only.

The clinical study experience

Participating in the BLOOM clinical study is designed to be as convenient and supportive as possible. The study will last about 16 weeks. During that time, the study team will ask general questions about your loved one's health, and perform study-related tests to monitor overall health, side effects, and changes in quality of life.

Throughout the study, a dedicated medical team will monitor your loved one's health. Support will be provided every step of the way.

